dc.creator | Varas R. | |
dc.creator | Ortiz F.C. | |
dc.date.accessioned | 2020-09-02T22:29:55Z | |
dc.date.accessioned | 2022-11-08T20:19:44Z | |
dc.date.available | 2020-09-02T22:29:55Z | |
dc.date.available | 2022-11-08T20:19:44Z | |
dc.date.created | 2020-09-02T22:29:55Z | |
dc.date.issued | 2019 | |
dc.identifier | 25, 45, 4755-4762 | |
dc.identifier | 13816128 | |
dc.identifier | https://hdl.handle.net/20.500.12728/6517 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5143296 | |
dc.language | en | |
dc.publisher | Bentham Science Publishers | |
dc.subject | Glial cross-talk | |
dc.subject | Microglia | |
dc.subject | Multiple Sclerosis | |
dc.subject | Neuroinflammation | |
dc.subject | Oxidative stress | |
dc.subject | Remyelination | |
dc.subject | immunoglobulin enhancer binding protein | |
dc.subject | interleukin 17 | |
dc.subject | interleukin 1beta | |
dc.subject | interleukin 22 | |
dc.subject | interleukin 23 | |
dc.subject | interleukin 4 | |
dc.subject | interleukin 6 | |
dc.subject | monocyte chemotactic protein 1 | |
dc.subject | muscarinic receptor blocking agent | |
dc.subject | ocrelizumab | |
dc.subject | reactive oxygen metabolite | |
dc.subject | reduced nicotinamide adenine dinucleotide phosphate oxidase | |
dc.subject | reduced nicotinamide adenine dinucleotide phosphate oxidase 2 | |
dc.subject | reduced nicotinamide adenine dinucleotide phosphate oxidase 4 | |
dc.subject | toll like receptor 4 | |
dc.subject | transcription factor Nrf2 | |
dc.subject | transforming growth factor beta | |
dc.subject | tumor necrosis factor | |
dc.subject | CD4+ T lymphocyte | |
dc.subject | demyelinating disease | |
dc.subject | disease severity | |
dc.subject | drug targeting | |
dc.subject | enzyme activity | |
dc.subject | gene expression | |
dc.subject | glia cell | |
dc.subject | human | |
dc.subject | multiple sclerosis | |
dc.subject | nervous system inflammation | |
dc.subject | nonhuman | |
dc.subject | oligodendrocyte precursor cell | |
dc.subject | oxidative stress | |
dc.subject | priority journal | |
dc.subject | remyelinization | |
dc.subject | Review | |
dc.subject | Th17 cell | |
dc.subject | cell communication | |
dc.subject | cytology | |
dc.subject | demyelinating disease | |
dc.subject | glia | |
dc.subject | inflammation | |
dc.subject | multiple sclerosis | |
dc.subject | myelin sheath | |
dc.subject | oligodendroglia | |
dc.subject | pathology | |
dc.subject | pathophysiology | |
dc.subject | Cell Communication | |
dc.subject | Demyelinating Diseases | |
dc.subject | Humans | |
dc.subject | Inflammation | |
dc.subject | Multiple Sclerosis | |
dc.subject | Myelin Sheath | |
dc.subject | Neuroglia | |
dc.subject | Oligodendroglia | |
dc.subject | Oxidative Stress | |
dc.title | Neuroinflammation in demyelinating diseases: Oxidative stress as a modulator of glial cross-talk | |
dc.type | Review | |